中国·金沙9570(官方)登录入口

Be the most trusted biotech company

2021-06-07

Henlius Has Released Two Clinical Studies of Anti-PD-1 mAb Serplulimab for the First Time at 2021 ASCO Annual Meeting
2021-06-01

Henlius Received IND Approval for Its Novel Anti-CD73 mAb HLX23 from US FDA
2021-05-21

Phase 3 Clinical Results of Rituximab Injection in RA Patients Was First Released at the 25th National Congress of Chinese Rheumatology Association
2021-05-14

Henlius Wins"Most Innovative Global Biopharmaceutical Company 2021"Hosted by GHP Magazine
2021-05-13

Henlius Will Release the RA Phase 3 Clinical Study Results of Its Rituximab Injection HLX01 at Two Congresses
2021-05-11

Henlius Entered into a Collaboration with NeuPharma of a BRAF Target Inhibitor
2021-05-10

Henlius will Release Two Clinical Studies of anti-PD-1 mAb Serplulimab in 2021 ASCO
2021-04-29

Biodrugs Published the Results of the International Multicentre Phase 3 Clinical Trial of 汉曲优®
2021-04-22

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review